Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor* | Zendy

Sebastian Rehberg | Zendy; Perenlei Enkhbaatar | Zendy; Janina Rehberg | Zendy; Erin La | Zendy; Nicky Ferdyan | Zendy; Steve Qi | Zendy; Kazimierz Wiśniewski | Zendy; Lillian D. Traber | Zendy; Claudio D. Schteingart | Zendy; Pierre Rivière | Zendy; Régent Laporte | Zendy; Daniel L. Traber | Zendy

Open Access

Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor*

Author(s) -

Sebastian Rehberg,

Perenlei Enkhbaatar,

Janina Rehberg,

Erin La,

Nicky Ferdyan,

Steve Qi,

Kazimierz Wiśniewski,

Lillian D. Traber,

Claudio D. Schteingart,

Pierre Rivière,

Régent Laporte,

Daniel L. Traber

Publication year - 2012

Publication title -

critical care medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.002

H-Index - 271

eISSN - 1530-0293

pISSN - 0090-3493

DOI - 10.1097/ccm.0b013e31824e0fe5

Subject(s) - vasopressin , agonist , medicine , endocrinology , arginine vasopressin receptor 1b , vasopressin receptor , desmopressin , arginine vasopressin receptor 2 , arginine , receptor , chemistry , antagonist , biochemistry , amino acid

To compare the effects on von Willebrand factor release of the mixed vasopressin type 1a and type 2 receptor agonist arginine vasopressin and the selective vasopressin type 1a receptor agonist FE 202158, [Phe2,Ile3,Hgn4,Orn(iPr)8]vasopressin, at doses required for the treatment of septic shock.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research